Steven N Seyedin
Overview
Explore the profile of Steven N Seyedin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harada G, Seyedin S, Heutlinger O, Azizi A, Hsu A, Rezazadeh A, et al.
Adv Radiat Oncol
. 2024 Dec;
10(1):101671.
PMID: 39655154
Purpose: Pelvic lymph node metastases (ypN+) after multiagent neoadjuvant chemotherapy (NAC) is a poor prognostic sign in nonmetastatic muscle-invasive bladder cancer (nmMIBC). We sought to create a nomogram predicting probability...
2.
Heutlinger O, Azizi A, Harada G, Harris J, Daneshvar M, Gin G, et al.
Cureus
. 2024 Oct;
16(9):e68945.
PMID: 39381448
Purpose This study aimed to identify factors associated with delays in initiating early salvage radiation therapy in prostate cancer patients with prostate-specific antigen (PSA) failure after prostatectomy. Methods We conducted...
3.
Seyedin S, Harada G, Garemanian E, Rafizadeh D, Kaakour D, Dwabe S, et al.
Cureus
. 2024 Aug;
16(7):e64781.
PMID: 39156348
Papillary renal cell carcinoma (pRCC) is a rare kidney cancer with limited treatment options and poor outcomes when metastatic. We present a case of a 42-year-old male with metastatic pRCC...
4.
Yeakel J, Seyedin S, Harada G, Hagopian G, Mahmood S, Bennett R, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001464
Y-90 Selective Internal Radiotherapy (SIRT) is an ablative therapy used for inoperable liver metastasis. The purpose of this investigation was to examine the impact of local control after SIRT on...
5.
Mar N, Dwabe S, Baranda M, Zarrabi K, Eturi A, Gulati S, et al.
Clin Genitourin Cancer
. 2023 Dec;
22(2):217-223.
PMID: 38087703
Introduction: Despite the introduction of various novel therapies for management of metastatic castrate resistant prostate cancer (mCRPC) in recent decades, available treatment options are finite and remain limited. Multiple historical...
6.
Poellmann M, Bu J, Liu S, Wang A, Seyedin S, Chandrasekharan C, et al.
Biosens Bioelectron
. 2023 Feb;
226:115117.
PMID: 36753988
A highly sensitive, circulating tumor cell (CTC)-based liquid biopsy was used to monitor gastrointestinal cancer patients during treatment to determine if CTC abundance was predictive of disease recurrence. The approach...
7.
Seyedin S, Bassalow R, Mawlawi O, Turner L, Patel R, Mazin S, et al.
Front Oncol
. 2022 Oct;
12:921473.
PMID: 36313653
Purpose: We investigated the feasibility of biology-guided radiotherapy (BgRT), a technique that utilizes real-time positron emission imaging to minimize tumor motion uncertainties, to spare nearby organs at risk. Methods: Volumetric...
8.
Dayyani F, Smith B, Nguyen N, Daly S, Hinojosa M, Seyedin S, et al.
Future Oncol
. 2022 May;
18(21):2615-2622.
PMID: 35603628
Current guidelines recommend neoadjuvant (NAC) and/or adjuvant chemotherapy for locally advanced gastric cancers (LAGCs). However, the choice and duration of NAC regimen is standardized, rather than personalized to biologic response,...
9.
Seyedin S, Watkins J, Mayo Z, Snow A, Laszewski M, Russo J, et al.
Adv Radiat Oncol
. 2021 Dec;
6(6):100778.
PMID: 34934861
Purpose: The cohort of patients with locally advanced prostate cancer (PC) and positive surgical margin(s) at radical prostatectomy (RP) who would benefit from salvage or adjuvant treatment is unclear. This...
10.
Seyedin S, Parekh K, Ginader T, Caster J
Ann Thorac Surg
. 2020 Oct;
112(2):459-466.
PMID: 33096068
Background: Approximately 40% of patients with esophageal cancer present with metastatic disease. Survival with palliative treatment is poor, and the benefit of aggressive focal therapies is unclear. This study aimed...